The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A Phase II Randomized, Placebo-Controlled Trial Evaluating Nintedanib versus Placebo as Prophylaxis against Radiation Pneumonitis in Patients with Unresectable Non-Small Cell Lung Cancer (NSCLC ) Undergoing ChemoRadiation Therapy (CRT): A National Comprehensive Cancer Network-Sponsored Study.
 
Grace K. Dy
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); OncoMed (Inst)
 
Eric S. Kim
No Relationships to Disclose
 
Megan Ann Baumgart
No Relationships to Disclose
 
Malcolm Mattes
No Relationships to Disclose
 
Patrick C. Ma
Honoraria - Daiichi Sankyo
Consulting or Advisory Role - Daiichi Sankyo
 
Shirish M. Gadgeel
Consulting or Advisory Role - ARIAD; AstraZeneca; Boehringer Ingelheim; Genentech/Roche; Novartis; Pfizer
Speakers' Bureau - Genentech/Roche
Research Funding - ACEA Biosciences (Inst); Acerta Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Halozyme (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst)
 
Julian R. Molina
No Relationships to Disclose
 
Kristopher Attwood
No Relationships to Disclose
 
Alex A. Adjei
No Relationships to Disclose